Citigroup Earnings Preview: Lowered Expectations David

New Post Public Reply Private Reply Replies (0) Message Board
Bible Feed

Citigroup Earnings Preview: Lowered Expectations


Citigroup reports QE June 2012 financial results on Monday, July 16, before market open

CEO Vikram Pandit, a Morgan Stanley alumni, gets yet another chance this quarter to provide excuses as to why Citigroup is so lousy. Never mind Pandit isn’t a banker and the incomprehensibility of him continuing to lead this disaster. At this point in Citigroup history, financial performance has been mixed: containing some good, some bad, mostly adequate.

The good last quarter was earnings per share, net revenues, operating income, net income, operating margin, and net margin rebounded strongly. Operating expenses decreased. The capital ratio did decrease slightly, but this was mostly the result of an increase in deposits.

The bad last quarter was first and foremost the wild card and game-changer: CVA/DVA 1 was a -$1.3 billion loss, resulting from the tightening of credit spreads. No matter the current quarter estimates, this nuclear bomb could detonate again and wipe out a significant portion of operating gains. If the bomb doesn’t ignite, a decent to strong quarter could randomly occur.

Citigroup goes through the meaningless exercise of releasing schedules and qualifying statements with this valuation adjustment excluded. That’s like showing a what-if box score excluding the other team’s 5 home runs.

Other concerns: Last quarter results were and the current quarter is projected to reveal year-ago performance deterioration. This can however be regained in one stronger quarter, but we are still waiting for that. The asset mix is negatively trending, net loans are decreasing while cash & investments are increasing in proportion to total assets. Return on assets is flat. Credit losses and claims are historically low, but slightly increased after the Q4 2011 multi-year low.

At 3-31-12, I have rated Citigroup a “D-” on a scale of A+ to G-. The median rating is “D” and the average rating was “C”. Financial position strength is weighted more than financial performance. The bank ratings review is here .

For the current Q2 2012, the average analysts’ EPS estimate is $0.91, which is a dip of -4% QoQ and a drop of -17% YoY. If Citigroup doesn’t rally and beat the Street, more financial ground is lost. CEO Pandit must then call for yet another retreat and retrenchment.

Estimated QE June 2012 Earnings per Share
Yahoo Finance Estimates: $0.91 avg, $0.79 low, $1.04 high, 21 analysts
Prior Quarter: $0.95
Prior Year: $1.09
Outlook: none provided

Prior Quarter: Citigroup Earnings Rebound on Adequate Results

Citigroup Income Statement Q1 2012 Citigroup financial performance rebounded with net revenues of $19.41 billion, net income of $2.93 billion, and earnings per share of $0.95. From the prior quarter Q4 2011, these were +13%, +207%, and +206%, respectively. From the prior year Q1 2011, these were -2%, -2%, and -4%, respectively. Both the operating margin and net margin increased QoQ but decreased slightly YoY to 20.96% and 15.10%, respectively. The operating expense ratio dipped to 49% and is near the historical average.

Citigroup Balance Sheet Q1 2012 Citigroup total assets increased to $1.94  trillion . Return on assets was steady at +0.57%, which is low but adequate. The capital to assets ratio decreased slightly to 9.45%. The regulatory Tier 1 capital ratio is 14.2% and the Tier 1 common ratio is 12.4%. All the capital ratios are adequate.

1 Credit valuation adjustment (CVA) on derivatives, net of hedges, and debt valuation adjustment (DVA) on Citigroup’s fair value option debt

Largest USA Banks Ratings: Capital One & U.S. Bancorp Tops, Goldman Sachs Last

Citigroup Earnings Rebound on Adequate Results

$ C $ XLF

Citigroup Inc. (C) Stock Research Links

C Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 14

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 5

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading
Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 3

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 6

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 6

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 7

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 6

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 7

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 7

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 3

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading

Top 5 Most Recently Viewed Articles

CRMLS Partners with Rayse to Enhance Agent-Client Transparency

Updated Category News Views 108

CRMLS Enhances Agent Value with Rayse Platform California Regional MLS (CRMLS), the leading multiple listing service in the nation, has made a significant move by integrating Rayse, a state-of-the-art agent value platform, into its offerings. This collaboration allows all CRMLS agent users to access Rayse at no cost directly through their MLS dashboard, marking a pivotal...

Continue Reading
UMG & TikTok's New Deal: A Boon for Artists?

Updated Category News Views 8

A New Era for Music Collaboration Universal Music Group and TikTok just cranked up the volume on their alliance, announcing a fresh, multi-year licensing agreement. This ain't just another handshake—it signals a seismic shift in how music gets discovered and consumed globally. Strengthened Bonds and Broadened Horizons Under this new agreement, TikTok will offer its...

Continue Reading
How an Investment in Thermo Fisher Scientific Transforms Wealth

Updated Category News Views 425

Unveiling the Growth of Thermo Fisher Scientific Investing is often seen as a pathway to wealth, and for those who placed their trust in Thermo Fisher Scientific Inc. (NYSE: TMO) two decades ago, the rewards have been substantial. This company, which specializes in scientific instrumentation, reagents, and consumables, has consistently outperformed the market. 20 Years of...

Continue Reading
European Energy A/S Launches Tender Offer for Green Bonds

Updated Category News Views 63

European Energy A/S Announces Its Tender Offer European Energy A/S has officially informed the market about a new opportunity for its bondholders. The company is targeting holders of its existing senior unsecured green bonds due in 2025 and 2026, inviting them to tender their bonds as part of a strategic financing move. Tender Offer Details Under this tender offer, which...

Continue Reading
Building a Rehabilitation Hospital: Encompass and BSA Join Forces

Updated Category News Views 170

Encompass Health and BSA Health System Join Forces Encompass Health Corp. and BSA Health System have embarked on a collaborative journey that aims to enhance rehabilitation services for patients recovering from various health challenges. This partnership marks a significant expansion in the healthcare landscape, focusing on providing dedicated rehabilitation care. A...

Continue Reading